Clinical Updates & Insights

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia, opening a new program for patients with desmoplastic small round cell tumors, translating groundbreaking tumor evolution insights into a new clinical trial strategy for patients with osteosarcoma, and leading cutting-edge research for improving patient outcomes after CAR T cell therapy.

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

Memorial Sloan Kettering Cancer Center (MSK) researchers presented results of their latest research at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7 to 10, 2024.

A Q&A with Jaap-Jan Boelens, MD, PhD, Chief of the Pediatric Transplant and Cellular Therapy Service at MSK.

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.

Tumor hypoxia on 18F-fluoromisonidazole (FMISO) positron emission tomography (PET) may serve as a reliable clinical biomarker of distant metastasis risk for patients with head and neck squamous cell carcinoma (HNSCC) after chemoradiotherapy (CRT), according to a study by MSK researchers.

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.

A Memorial Sloan Kettering Cancer Center (MSK) research team has identified a new, rare type of small cell lung cancer (SCLC) — dubbed “atypical SCLC” — that primarily affects younger people who have never smoked.

Memorial Sloan Kettering Cancer Center (MSK) experts shared the results from cutting-edge advances in cancer research at the European Society of Medical Oncology (ESMO) Congress 2024, held in Barcelona, Spain, September 13 to 17, 2024.